Quick Read
- Dr. Mariano Barbacid’s team at Spain’s CNIO developed a triple-drug therapy for pancreatic cancer.
- The therapy completely eliminated aggressive pancreatic tumors in mouse models.
- No relapse was observed for over 200 days in treated subjects.
- It targets three key proteins: KRAS, EGFR, and STAT3, to prevent tumor resistance.
- Clinical trials in humans are not yet feasible due to regulatory and funding hurdles.
MADRID (Azat TV) – A research team led by Dr. Mariano Barbacid at Spain’s National Center for Oncological Research (CNIO) has reported a significant breakthrough in treating pancreatic cancer, a notoriously aggressive and hard-to-treat malignancy. Their novel triple-drug therapy completely eliminated aggressive pancreatic tumors in mouse models, with no relapse observed during extended follow-up, signaling a potential new direction for combating a disease with historically low survival rates.
The findings, presented by the Cris Against Cancer Foundation in Madrid and published in the Proceedings of the National Academy of Sciences (PNAS), detail a combination of three inhibitors that effectively targets and eradicates tumor cells, keeping subjects cancer-free for over 200 days without significant adverse effects. This development is particularly notable given the minimal advancements in pancreatic cancer treatment options over the past five years.
Mariano Barbacid’s Triple Therapy Strategy
Dr. Barbacid’s innovative approach specifically targets three critical proteins: KRAS, EGFR, and STAT3. KRAS is mutated in approximately 90% of pancreatic cancer cases and is a key driver of tumor cell proliferation and treatment resistance. Standard therapies often fail because these tumors rapidly adapt, bypassing single-target drugs by activating alternative molecular pathways.
By simultaneously blocking KRAS and its alternative escape routes, the triple therapy prevents cancer cells from developing resistance. The combination includes an experimental KRAS inhibitor, a drug already approved for lung cancer, and a protein degrader. This coordinated inhibition of multiple pathways proved effective in three different animal models, leading to complete tumor regression and preventing recurrence.
The Challenge of Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive forms of cancer, with a five-year survival rate below 10%. Its rapid progression, early metastasis, and inherent resistance to conventional treatments have made it a formidable challenge for oncologists worldwide. The lack of significant progress in recent decades underscores the urgency for novel therapeutic strategies.
Oncologist Diego Kaen highlighted the profound significance of these results, noting that Dr. Barbacid’s breakthrough could usher in a new era of therapy focused on comprehensive KRAS inhibition and the simultaneous neutralization of tumor escape routes that have previously rendered treatments ineffective.
Dr. Barbacid’s Pioneering Cancer Research
Dr. Mariano Barbacid is widely recognized as one of Europe’s most influential cancer researchers. In the early 1980s, his pivotal work led to the identification of the first human oncogene, a discovery that fundamentally reshaped modern cancer biology and established the genetic basis of the disease. For over four decades, Dr. Barbacid has consistently focused on KRAS-driven tumors, which are considered among the hardest cancers to treat. His sustained dedication to understanding and combating the KRAS pathway lends substantial weight to the current findings within the scientific community.
The study, conducted at CNIO with significant support from the Cris Against Cancer Foundation, which has invested over 2 million euros since 2020, followed established experimental protocols and underwent independent peer review before publication. CNIO officials emphasized the robust scientific safeguards in place, countering any online speculation regarding the findings.
Path to Clinical Trials: Hurdles and Hope
While the results are highly encouraging, Dr. Barbacid has cautioned that clinical trials in humans are not yet feasible. Significant regulatory hurdles must be navigated, particularly concerning the combined use of these three inhibitors. Expediting this process will require appropriate funding and robust bureaucratic support, a point underscored by Lola Manterola, president of the Cris Against Cancer Foundation, who stressed the need for continued governmental assistance.
Future research will focus on increasing the number of patient tumor samples and investigating metastases to better identify which individuals might benefit most from these therapies. Optimizing the drug combination for human patients will be a complex endeavor, but the authors believe these findings provide a clear and promising direction for future clinical research.
This comprehensive approach, targeting multiple survival mechanisms simultaneously, represents a crucial paradigm shift in the fight against pancreatic cancer, moving beyond the limitations of single-drug strategies that tumors have historically circumvented.